Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Trial Profile

Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2018

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms D-STOP Trial
  • Most Recent Events

    • 01 Jan 2018 Results published in the Cancer Science
    • 06 Dec 2016 Status changed from recruiting to completed.
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top